Navigation Links
Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements
Date:3/27/2008

BERKELEY HEIGHTS, N.J., March 27 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced that the NASDAQ Listing Qualifications Panel has granted the Company's request for an extension of time to achieve full compliance with the applicable NASDAQ listing requirements. Pursuant to the Panel's decision, the listing of the Company's common stock will be transferred from The NASDAQ Global Market to The NASDAQ Capital Market, effective with the open of trading on Friday, March 28, 2008. The Company will continue to trade under its existing symbol, GNTA.

As disclosed on November 16, 2007 and January 11, 2008, the Company was previously notified by NASDAQ that it no longer satisfied the stockholders' equity requirement for continued listing on The NASDAQ Global Market, as set forth in Marketplace Rule 4350(a)(3). In response, the Company appeared before the Panel at a hearing on February 21, 2008.

The Company's continued listing on The NASDAQ Capital Market is subject to the Company's compliance with certain conditions, including evidence of the Company's ability to sustain compliance with the $2.5 million stockholders' equity requirement, as set forth in Marketplace Rule 4310(c)(3), and the submission of the required transfer application to NASDAQ within the next seven days. The Company currently expects to be able to comply with the Panel's conditions for continued listing on The NASDAQ Capital Market; however, there can be no assurance that the Company will be able to achieve or sustain such compliance.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: http://www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward-looking statements include, without limitation, statements about:

-- the Company's ability to obtain necessary regulatory approval for

Genasense(R) from the U.S. Food and Drug Administration ("FDA") or

European Medicines Agency ("EMEA");

-- the safety and efficacy of the Company's products or product

candidates;

-- the Company's assessment of its clinical trials;

-- the commencement and completion of clinical trials;

-- the Company's ability to develop, manufacture, license and sell its

products or product candidates;

-- the Company's ability to enter into and successfully execute license

and collaborative agreements, if any;

-- the adequacy of the Company's capital resources and cash flow

projections, and the Company's ability to obtain sufficient financing

to maintain the Company's planned operations;

-- the adequacy of the Company's patents and proprietary rights;

-- the impact of litigation that has been brought against the Company and

its officers and directors and any proposed settlement of such

litigation;

-- the Company's ability to retain compliance with the NASDAQ's listing

qualifications; and

-- the other risks described under Certain Risks and Uncertainties Related

to the Company's Business, as contained in the Company's Annual Report

on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2007 and its most recent quarterly report on Form 10-Q.

CONTACT:

Nichol Harber

Genta Investor Relations

908-286-3980

info@genta.com


'/>"/>
SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Auditors for Genta Incorporated Express Going Concern Qualification
2. Genta Announces Senior Management Changes
3. Genta Announces Common Stock Offering of Approximately $3.1 Million
4. Genta Incorporated to Present at the BIO CEO & Investor Conference
5. Genta Receives Notice of Non-Compliance With NASDAQ Rule
6. Genta Receives NASDAQ Non-Compliance Notice
7. Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference
8. Syngenta and The Royal Society of Chemistry Launch African Science Initiative
9. Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market
10. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
11. Syngenta Licenses Chromatin Gene Stacking Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... SAN DIEGO, Feb. 11, 2016  Neurocrine Biosciences, Inc. (NASDAQ: ... year ended December 31, 2015. --> ... reported a net loss of $29.3 million, or $0.34 loss per ... loss per share for the same period in 2014. For the ... of $88.9 million, or $1.05 loss per share, as compared to ...
(Date:2/11/2016)... Germany and GERMANTOWN, ... QGEN ; Frankfurt Prime Standard: QIA) today announced ... RNA Panels for gene expression profiling, expanding QIAGEN,s portfolio ... The panels enable researchers to select from over 20,000 ... and discover interactions between genes, cellular phenotypes and disease ...
(Date:2/11/2016)... , Feb. 11, 2016  Spectra BioPharma Selling Solutions ... that provides biopharma companies the experience, expertise, operational ... deploy outsourced sales teams. Created in concert with ... both the strategic and tactical needs of its ... solutions through both personal and non-personal promotion. ...
(Date:2/11/2016)... York, NY (PRWEB) , ... ... ... (BPI), a business-to-business publication dedicated to delivering cutting-edge information focused on the ... Healthcare Life Sciences to become a premier sponsor of the 2016 BioProcess ...
Breaking Biology Technology:
(Date:1/20/2016)... LONDON , Jan. 20, 2016 A ... positioned to directly benefit from the explosion in genomics ... from Howe Sound Research. A range of dynamic trends ... ...... - personalized medicine - pharmacogenomics - pathogen ... economies with large markets - greater understanding of the ...
(Date:1/20/2016)... Calif. , Jan. 20, 2016  Synaptics ... of human interface solutions, today announced sampling of ... solution for wearables and small screen applications including ... as printers. Supporting round and rectangular shapes, as ... offers excellent performance with moisture on screen, while ...
(Date:1/15/2016)... SAN JUAN, Puerto Rico , Jan. 15, 2016 ... forcing companies big and small to find new ways ... data driven culture. iOS and ... their device based on biometrics, transforming it into a ... can request that users swipe their fingerprint on their ...
Breaking Biology News(10 mins):